2012 Short Takes
He's back. George Carlo, that is. Though not in the cell phone game, but baseball. Carlo has reinvented himself, this time as a brain scientist. He is now working with Brian Peterson, who calls himself the "Performance Enhancement Instructor" for the Detroit Tigers, according to the Web site Fangraphs. This is Peterson on Carlo's qualifications: "He's an MD, he has a PhD in pathology, and he also has a law degree. By trade, he's a brain researcher. George is a research scientist and an expert on how the body works in conjunction with the brain." That MD degree is news to us. Peterson might have added industry fixer and con artist to Carlo's résumé. After all he used to be a pitchman for BioPro, which sold useless gizmos that promised protection against cell phone radiation. And in the 1990s, Carlo ran the biggest scam of all, WTR, the CTIA-financed industry research program on cell phone radiation risks (see "WTR and the Betrayal of the Public Trust"). Twenty years later, no one yet knows what happened to the $25 million that was supposed to have been spent on health research.
“I am the happiest man alive,” says Robert Dill-Bundi, the Swiss Olympic cycling champion. Dill-Bundi developed a glioblastoma multiforme, an aggressive, usually fatal, type of brain tumor, but is still alive years after being treated with electric fields. The therapy was developed by Novocure, an Israeli company (see: “Weak Kilohertz Electric Fields Kill Tumor Cells”). Bill Doyle, Novocure’s chairman, describes how the treatment works in a lecture recently posted by TEDMED, an offshoot of TED, the technology/entertainment/design consortium. Take a look at the 16-minute video and see what might well be the future of cancer treatment.
Carl Blackman of the U.S. EPA has published an editorial comment accompanying the new Boris Pasche paper on modulating frequencies to treat cancer in the British Journal of Cancer. In "Treating Cancer with Amplitude-Modulated Electromagnetic Fields: A Potential Paradigm Shift, Again?," Blackman puts Pasche's new findings in context with the work on amplitude-modulated (AM) signals by Ross Adey and Suzanne Bawin from the mid-1970s, as well as Blackman's own studies from the same era. Blackman concludes: "The group of [Pasche's] three papers demonstrate a new, potentially important modality in the treatment of cancer that could lead to a paradigm shift in disease treatment. I hope that this medical application of AM-EMF will not be allowed languish without funding, as happened with its previous, ill-fated emergence." The editorial is open access, as is the Pasche paper.
The Observer in the U.K. is the first mainstream news outlet to cover Boris Pasche and Frederico Costa's cancer therapy that uses weak RF radiation to shrink liver tumors. The story was posted today by Robin McKie with the headline, "Hopes Rise for New Cancer Treatment After Tests with Electromagnetism." McKie includes a cautious assessment from Cancer Research UK, a leading charity and the publisher of the British Journal of Cancer. Pasche reveals that he has a go-ahead from the FDA to embark on large-scale trials —and that he is now looking for financial support. (See our earlier story on Pasche's TheraBionic therapy and "Specific Frequencies Block Growth of Cancer Cells," his most recent paper). January 8… Today, Sunday, the Daily Mail picked up the story from the Observer under the headline, "Hopes of Cancer Breakthrough with Treatment Using Electromagnetic Fields To Shrink Tumours.